TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with pathologically proven cutaneous T-cell lymphoma (CTCL), disease stage IIB to IVB, patients must be in at least a partial response-PR (skin and lymph nodes) after receiving other non-allogeneic transplant therapy, age \</= 70 years, Zubrod performance status 0 or 1, left ventricular ejection fraction \>/= 50% or approved for transplant by a cardiologist, DLCO \>/= 50% predicted or approved for transplant by a pulmonologist, serum creatinine \</= 1.5 mg/dL, serum bilirubin \< 2mg/dL. SGPT \< 3 x upper limit of normal, and no previous history of allogeneic transplantation.~2. Donor: HLA-compatible related (HLA-A, -B, -DRB1 matched or with one-antigen mismatch) or HLA-compatible unrelated (HLA-A, -B, -C and -DRB1 matched or with one-antigen mismatch).~Exclusion Criteria:~1) Patients cannot have active central nervous system (CNS) disease.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Fludarabine + Melphalan with PBPC (Type: EXPERIMENTAL): Fludarabine 25 mg/m\^2 intravenous (IV) daily for 5 Days prior to Allogeneic Transplant, Melphalan 70 mg/m\^2 IV daily for 2 Days prior to IV Allogeneic Transplant following Fludarabine \& Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 \& -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot of Preemptive Pharmacogenetics in Medically Underserved Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (18 years or older) with active prescriptions for at least 3 medications documented within the EHR.~* At least 1 drug/drug class that could be informed by the pharmacogenetics test panel available at the UF.~* A medication change within the past 6 months (associated with a healthcare provider encounter).~* Self-identify as black or Latino.~Exclusion Criteria:~* Patients with any history of pharmacogenetic testing within the EHR.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Panel-based pharmacogenetic genotyping (Type: EXPERIMENTAL): All patients will receive clinical preemptive pharmacogenetic testing. Genotype results and consult notes will returned in the EHR pre-emptively. Data on implementation success metrics and PROs via patient report and TSQM measures will be collected. In addition, data on effectiveness outcomes and socioeconomic measures will be collected via the EHR and patient report, respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Pain OneSheet Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary care provider (including Family Medicine, Internal Medicine, Med-Peds, and General Medicine)~* Can prescribe medication (i.e., Doctor of Medicine (MD), Nurse Practitioner (NP), Physicians Assistant (PA))~* Sees patients at a primary care clinic at one of the two participating hospital systems~Exclusion Criteria:~* Does not practice primary care~* Does not regularly see patients at a primary care clinic at one of the two participating hospital systems~* Cannot prescribe medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- OneSheet access (Type: EXPERIMENTAL): PCPs who receive access to, and training in the Chronic Pain OneSheet, and use it while caring for patients with chronic pain.
- Normal practice (Type: NO_INTERVENTION): PCPs who do not receive access to, or training in the Chronic Pain OneSheet, and care for patients with chronic pain as they would normally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of an Intravenous Solution of JNJ-39588146 or Placebo in Patients With Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have been diagnosed with heart failure~* Women must be either postmenopausal or have been surgically sterilized at least 6 months ago~* Males must be willing to use an acceptable birth control method for 3 months after the last dose of study medication.~Exclusion Criteria:~* Patients must not have had an heart-assist device or heart transplant or be in imminent need of one~* Patients must not have had an ischemic attack within the last 6 months or a heart attack within the last month~* Patients must not have lung disease or congenital heart failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 86 Years
- Healthy Volunteers: f

Study Arms:
- Part 1 (Main Study) (Type: EXPERIMENTAL): 3 consecutive 1-hour infusions of JNJ-39588146 5, 15, or 30 ng/kg/min or matching placebo
- Part 2 (Extended Infusion Sub-Study) (Type: EXPERIMENTAL): 1 18-hr infusion of JNJ-39588146 of the highest tolerated dose from Part 1 of the study or matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Evaluate the Efficacy and Safety of Pitavastatin/Fenofibrate in Complex-dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* High risk patient to Coronary Heart Disease~* At visit 1(Screening)~  1. If treated with Pitavastatin 2mg monotherapy 4 weeks prior to this study : LDL-C\<100mg/dL and 150mg/dL≤TG\<500mg/dL, randomize without run-in period~ 2. If non treated with Pitavastatin 2mg monotherapy 4 weeks prior to this study : LDL-C≥100mg/dL and 150mg/dL≤TG\<500mg/dL, treatment of Pitavastatin 2mg for 4 weeks(run-in period)~* LDL-C\<100mg/dL and 150mg/dL≤TG\<500mg/dL after 4 weeks of Pitavastatin 2mg monotherapy~Exclusion Criteria:~* Subject with acute artery disease~* Subject with congestive heart failure(NYHA class III\~IV) or uncontrolled arrhythmia~* Secondary or iatrogenic dyslipidemia caused by hypothyroidism, nephrotic syndrome etc.~* AST or ALT \> 2XULN, Serum Creatinine \> 2.5mg/dL, Creatinine phosphokinase \> 2XULN~* Subject with gall bladder disease or pancreatitis~* Uncontrolled hypertension~* Endocrine or metabolic disease affected on serum lipid or liprotein~* Subject with medical history of myopathy or rhabdomyolysis caused by Statin treatment, hereditary myopathy or family history~* Not eligible to participate for the study at the discretion of investigator

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HL-PIF cap.160/2mg + Placebo (Type: EXPERIMENTAL): * Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg~* once a day
- Livalo tab. 2mg + Placebo (Type: ACTIVE_COMPARATOR): * Pitavastatin ca 2mg~* once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Opioid Prescription After Cesarean Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Post cesarean delivery (combined vaginal/cesarean deliveries are not eligible)~* Singleton, twin or triplet gestation~Exclusion Criteria:~* An opioid prescription filled during the current pregnancy~* Known history of opioid use disorder, by medical record review~* Contraindication to opioids (oxycodone)~* Contraindications to both acetaminophen and ibuprofen~* Significant surgical procedures (e.g., hysterectomy) prior to randomization as pain trajectory will be completely different~* Fetal or neonatal death prior to randomization~* Inability to randomize within 1 day before planned discharge from the hospital~* Inability to participate in shared decision making as assessed by research staff~* Language barrier (non-English or Spanish speaking)~* Participation in this trial in a previous pregnancy~* Participation in another intervention study that influences the primary outcome in this trial

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Individualized Opioid Prescription (Type: EXPERIMENTAL): Individualized opioid prescription protocol and shared decision making
- Fixed Opioid Prescription (Type: OTHER): Fixed opioid prescription of 20 tablets of oxycodone 5mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetics taking metformin IR or XR greater than or equal to 850mg and less than or equal to 1500mg only for at least 8 weeks prior to screening~* A1c: 7.5-11% (at screening)~* BMI less than or equal to 45 kg/m2~Exclusion Criteria:~* Significant cardiovascular history~* Active liver disease, renal impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Saxagliptin
- 2 (Type: ACTIVE_COMPARATOR): Metformin Extended Release

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of chronic obstructive pulmonary disease.~2. Relatively stable airway obstruction with post FEV1\< 80% predicted normal and post FEV1/FVC \<70%.~3. Male or female patients, 40 years of age or older.~4. Smoking history of more than 10 pack years.~Exclusion criteria:~1. Significant disease other than COPD~2. Clinically relevant abnormal lab values.~3. History of asthma.~4. Diagnosis of thyrotoxicosis~5. Diagnosis of paroxysmal tachycardia~6. History of myocardial infarction within 1 year of screening visit~7. Unstable or life-threatening cardiac arrhythmia.~8. Hospitalization for heart failure within the past year.~9. Known active tuberculosis.~10. Malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years~11. History of life-threatening pulmonary obstruction.~12. History of cystic fibrosis.~13. Clinically evident bronchiectasis.~14. History of significant alcohol or drug abuse.~15. Thoracotomy with pulmonary resection~16. Oral ß-adrenergics.~17. Oral corticosteroid medication at unstable doses~18. Regular use of daytime oxygen therapy for more than one hour per day~19. Pulmonary rehabilitation program in the six weeks prior to the screening visit~20. Investigational drug within one month or six half lives (whichever is greater) prior to screening visit~21. Known hypersensitivity to ß-adrenergic drugs, anticholinergics, BAC, EDTA~22. Pregnant or nursing women.~23. Women of childbearing potential not using a highly effective method of birth control~24. Patients who are unable to comply with pulmonary medication restrictions

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tiotropium+olodaterol high dose FDC (Type: EXPERIMENTAL): Once daily 2 puffs solution for inhalation Respimat
- tiotropium+olodaterol low dose FDC (Type: EXPERIMENTAL): Once daily 2 puffs solution for inhalation Respimat
- olodaterol (Type: ACTIVE_COMPARATOR): Once daily 2 puffs solution for inhalation Respimat
- tiotropium low dose (Type: ACTIVE_COMPARATOR): Once daily 2 puffs solution for inhalation Respimat
- tiotropium high dose (Type: ACTIVE_COMPARATOR): Once daily 2 puffs solution for inhalation Respimat

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Innovative Approaches for Minor Consent: Consent 2.0

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Note: Age limits apply to adolescent participants and to the adolescent children of parent participants.~Adolescent Inclusion Criteria~* Age 14-17 inclusive~* Able to read and speak English~* HIV status is negative or unknown~* Engaged in high-risk sexual activity in the last six months~Adolescent Exclusion Criteria~* Child of a parent already enrolled in the study~Parent Inclusion Criteria~* Able to read and speak English~* Parent or guardian of an adolescent who is between ages 14-17~* The parent/guardian's adolescent's HIV status is either negative or unknown~Parent Exclusion Criteria~* Parent of a child already enrolled in the study

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Adolescents: Consent Condition 1 (Type: ACTIVE_COMPARATOR): Autonomous minor consent
- Adolescents: Consent Condition 2 (Type: ACTIVE_COMPARATOR): Adult permission required
- Adolescents: Consent Condition 3 (Type: ACTIVE_COMPARATOR): Parental permission required
- Parents: Consent Conditions 1-3 (Type: ACTIVE_COMPARATOR): Autonomous minor consent, adult permission required, and parental permission required

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sacral Nerve Stimulation Therapy for the Treatment of Chronic Fecal Incontinence

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent.~* 18 years of age or older.~* Patient is diagnosed with chronic fecal incontinence of a duration greater than 6 months (\>12 months post-vaginal childbirth) and defined as \> 2 incontinent episodes on average per week of more than staining recorded during the baseline diary period.~* Failed or are not candidates for more conservative treatments.~* Willing and competent to completely and accurately fill out bowel diaries and questionnaires throughout the study.~Exclusion Criteria:~* Congenital anorectal malformations.~* Active participation in another bowel disorder investigational study.~* Present rectal prolapse.~* Previous rectal surgery (such as rectopexy or resection) or sphincteroplasty done \< 12 months prior to study enrollment (24 months for cancer).~* Neurological diseases such as clinically significant peripheral neuropathy or complete spinal cord injury (i.e. paraplegia).~* Grade III hemorrhoids.~* Known or suspected organic disorders of the bowel (i.e. Inflammatory bowel disease such as Crohn's or ulcerative colitis).~* Chronic watery diarrhea, unmanageable by drugs or diet, as primary cause of fecal incontinence. (Incontinent episodes with a Bristol stool consistency of \> 6 for \> 4 days during the baseline diary period will be exclusionary, unless the investigator determines that the diary is not indicative of chronic watery diarrhea.)~* Pregnancy or planned pregnancy.~* Patients for whom patient materials are not available in a language understood by the patient.~* Life expectancy of less than one year.~* Patient characteristics indicating a poor understanding of the study or poor compliance with the study protocol (i.e., patients unable to adequately operate equipment, patients unwilling or unable to return for scheduled follow-up visits).~* Patients with a history of pelvic irradiation who present with visible or functional effects of irradiation.~* Patients with active anal abscesses or fistulas.~* Patients with anatomical limitations that would prevent the successful placement of an electrode.~* Patients with knowledge of planned MRIs, diathermy, microwave, or RF energy.~* Patients with other implantable neurostimulators, pacemakers or defibrillators.~* Defect of external anal sphincter of \>60 degrees or amenable to surgical repair.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* laboratory confirmed positive test for SARS-CoV-2~* admitted to ICU because of critical illness due to covid-19~Exclusion Criteria:~* patients with treatment for thromboembolic complications at arrival to the ICU~* short ICU length of stay defined as discharged the same or the following day as ICU admission

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- thrombose prophylaxis (Type: None): The dose used to prevent thromboembolic complication in critically ill
- double thrombose prophylaxis (Type: None): Double the dose used to prevent thromboembolic complication in critically ill
- full dose anticoagulant (Type: None): Dose used to treat thromboembolic event

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Documented human immunodeficiency virus type 1 (HIV-1) infection~* Never been treated with an antiretroviral (ARV) treatment or therapeutic HIV vaccine, or received less than or equal to 2 weeks treatment prior to screening with an nucleoside reverse transcriptase inhibitors~* HIV-1 plasma viral load above 5000 HIV-1 RNA copies per milliliter, at screening~* Cortisol of at least 550 nano moles per liter (19.9 microgram per deciliter) at screening~* Sensitivity to investigator selected nucleosides, at screening~Exclusion Criteria:~* Currently having active Acquired Immunodeficiency Syndrome (AIDS) defining illness~* Known or suspected acute (primary) HIV-1 infection~* Any current or history of adrenal disorder, and an acute hepatitis A, B, or C infection~* Documented genotypic evidence of Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) resistance at screening~* Pregnant or breastfeeding females~* Not agree to protocol-defined effective use of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TMC278 25 mg (Type: EXPERIMENTAL): Participants will receive TMC278 25 mg once daily up to Week 96. Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
- TMC278 75 mg (Type: EXPERIMENTAL): Participants will receive TMC278 75 mg once daily up to Week 144. Later on, participants will receive TMC278 25 mg once daily up to Week 240.
- TMC278 150 mg (Type: EXPERIMENTAL): Participants will receive TMC278 150 mg once daily up to Week 96. Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
- Efavirenz (Type: ACTIVE_COMPARATOR): Participants will receive efavirenz 600 mg once daily up to Week 96. Later on, participants will have an option to continue on efavirenz until Week 144 or until Week 240.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete